SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934
For the month of November 2014
BioLineRx Ltd. (Translation of Registrant's name into English)
P.O. Box 45158 19 Hartum Street Jerusalem 91450, Israel
(Address of Principal Executive Offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Form 20-F ☑ Form 40-F □
Indicate by check mark whether the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) und the Securities Exchange Act of 1934:
Yes □ No 🗵

On November 10, 2014, at 10:00 am EDT, the Registrant will conduct a conference call concerning its operating results for the quarter ended September 30, 2014. The presentation with information relating to such conference call is filed as Exhibit 1 to this Report on Form 6-K.

This Form 6-K, including all exhibits hereto, is hereby incorporated by reference into all effective registration statements filed by the Company under the Securities Act of 1933.

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

BioLineRx Ltd.

By: /s/ Philip Serlin
Philip Serlin
Chief Financial and Operating Officer


Dated: November 10, 2014



Forward Looking Statements

This presentation contains "forward-looking statements."
These statements include words like "may," "expects,"
"believes," "plans," "scheduled," and "intends," and describe opinions about future events. These forward-looking statements involve known and unknown risks and uncertainties that may cause the actual results, performance or achievements of BioLineRx to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.





Chief Executive Officer Kinneret Savitsky, Ph.D.

Update on Operations and Lead Programs



Promising Platform for AML and Other Hematological Indications Promising Platform for AML and Other Hematological Indications Robust apoptosis of cancer cells Substantial mobilization of cancer cells from bone march Synergizes with other AML treatments Strong global IP estate: 13 issued/25 patents pending worldwide Received orphan drug status for two lead indications Significant Current and Future Potential for EL-8040 AML (Phase 2) Stem cell mobilization (Phase 1)

BL-8040: Acute Myeloid Leukemia (AML)

Current Status - Completing Phase 2 dose escalation stage

- ✓ Dec. 2013: Announced promising partial dose escalation phase results.
- ✓ Nov. 2014: Increased dosing based on encouraging efficacy and excellent safety.
 - Unanimous recommendation by Clinical Advisory Board to amend study protocol
 - Increasing total number of patients from 50 to 70
- Early 2015: Complete dose escalation phase
- H2 2015: Complete full study

FLT3-Positive AML - ~30% of AML; associated with poor prognosis

- ✓ Jun/Jul. 2014: Presented data showing synergy with AC220 (Quizartinib)
 - Minimized residual AML disease (mouse model)
 - Reduces level of BM cancer cells in vivo by at least one order of magnitude
 - Prevented reduction in normal white blood cells seen with AC220 alone
- ✓ September 2014: Daiichi Sankyo announced acquisition of Ambit for ~\$410 million
 - Potential high-value future opportunity for BL-8040

Stem Cell Mobilization Jun. 2014: Received approval from Israeli Ministry of Health to begin human studies Sep. 2014: Initiated two-part Phase 1 study Part 1: Safety and tolerability as a standalone the soly Dose escalation (randomized, double-blind, placebo-controlled, 32 volunteers Part 2: Quantify stem cell mobilization capacity and yield Open-label study; eight volunteers (at optimal dose from Part 1) Late 2014/Early 2015: Report final results

BL-7010: NOVEL GLIADIN BINDING POLYMER FOR CELIAC DISEASE

Exciting progress in a fast-growing market

- Significantly increased Pharma interest
- Very high-need and underserved population

Phase 1/2 study completed in celiac patients:

- ✓ Mar. 2014: Completed dose escalation stage; initial edition of the peaker dose stage.
- ✓ Jul. 2014: Reported unblinded results of repeated to the stage (14 days, 3x per day)
 - No serious or dose-limiting toxicity; No systemic absorption
 - Investigated lower repeated doses due to repeated doses due to repeated (GI) adverse events
- ✓ Aug. 2014: Received notice of allowance for 15.5 patent covering BE-7010 until 2026
- ✓ Nov. 2014: Reported final results fully confirming previous final results.
 - No systemic absorption likely to support medical device classification in EU
 - Substantially reduced level GI-related adverse events
 - Optimal safe dose selected for randomized, placebo controlled efficacy study to commence in H2 2015

BL-1040: FIRST-IN-CLASS BIOABSORABLE CARDIAC MATRIX FOR PREVENTION OF VENTRICULAR REMODELING FOLLOWING AMI

- Pivotal CE Mark registration trial continues on schedule
 - Trial enrolled >280 patients of ~300 patients
 - Endpoints: End diastolic volume index, QLQ, six-minute walk test
- Still expect to complete enrollment by year-end 2014
- Study completion anticipated in mid-2015
- Will be followed by CE Mark filing
- Previous Phase 1/2 study results published in cereviewed Circulation
 - BL-1040 was well tolerated following the core as the
 - Sustained safety profile after six months of following
 - ECG at six months showed preservation of left ve the lar functions

Chief Financial & Operating Officer
Philip A. Serlin, CPA, MBA

Third Quarter 2014 Financial Overview



Corporate Highlights

- Strong current cash position: \$29.6 million at September 30, 2014
 - Funds operational capital through end of 2016
 - Expect to reach several value inflection points during this time
- Broad U.S. institutional investor base
 - U.S. investors hold roughly 60% of total shares outstanding
- Upcoming conferences
 - Investor/Analyst Breakfast in December on BL-8040 2015 development plans
 - Biotech Showcase in San Francisco in January
 - Bio-CEO Conference in New York in February
 - Roth Conference in LA in March

Financial Overview

(in USD at 30-Sep-14 exchange rate)

Research and development

- Total R&D expenses decreased by \$4.4 million, to \$8.0 million for the nine months ended September 30, 2014
 - Primarily from termination of the BL-1020 CLARITY clinical trial in March 2013, as well as certain one-time costs associated with several clinical-stage projects in 2013
 - Decrease partially offset by increased spending on the BL-7010 (celiac) project

Sales and marketing

- S&M expenses increased by \$0.2 million, to \$0.9 million for the nine months ended September 30, 2014
 - Increase resulted primarily from professional fees in connection with increased business development activities

Financial Overview

(in USD at 30-Sep-14 exchange rate)

General and administrative


- G&A expenses decreased by \$0.2 million, to \$2.5 million for the nine months ended September 30, 2014
 - Primarily due to a one-time expense for professional services in the 2013 period

Non-operating income

- Non-operating income increased by \$0.7 million, to \$3.2 million in for the nine months ended September 30, 2014
 - Primarily stems from fair-value adjustment related to warrant liability

Financial income/expenses

- Net financial income was \$1.7 million for the nine months ended September 30, 2014, compared to net financial expenses of \$0.9 million in the 2013 period
 - Changes result primarily from changes in average exchange rate of NIS to USD



Bench to Bedside to Partner







THANK YOU!

QUESTIONS?

